FY2025 Earnings Estimate for AURA Issued By Leerink Partnrs

Aura Biosciences, Inc. (NASDAQ:AURA) – Analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for Aura Biosciences in a research note issued on Sunday, November 16th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($1.84) per share for the year, up from their previous forecast of ($1.98). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q4 2025 earnings at ($0.45) EPS, FY2026 earnings at ($2.11) EPS and FY2027 earnings at ($2.23) EPS.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, November 13th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06.

Several other equities research analysts have also weighed in on AURA. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Wednesday, August 13th. Zacks Research upgraded shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Aura Biosciences Price Performance

NASDAQ:AURA opened at $5.41 on Wednesday. The company has a market capitalization of $343.54 million, a P/E ratio of -2.79 and a beta of 0.45. The business has a fifty day simple moving average of $5.97 and a two-hundred day simple moving average of $6.22. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $9.53.

Institutional Investors Weigh In On Aura Biosciences

Several large investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. bought a new stake in shares of Aura Biosciences during the 2nd quarter valued at about $31,926,000. Nantahala Capital Management LLC raised its stake in Aura Biosciences by 67.1% in the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock valued at $13,257,000 after purchasing an additional 850,000 shares in the last quarter. Long Focus Capital Management LLC lifted its position in Aura Biosciences by 30.8% during the first quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock valued at $19,453,000 after purchasing an additional 781,808 shares during the last quarter. Acorn Capital Advisors LLC bought a new stake in Aura Biosciences during the first quarter valued at approximately $3,460,000. Finally, Vanguard Group Inc. grew its stake in Aura Biosciences by 16.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company’s stock worth $17,863,000 after buying an additional 413,001 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Insider Buying and Selling at Aura Biosciences

In related news, insider Janet Jill Hopkins sold 17,109 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $5.42, for a total transaction of $92,730.78. Following the completion of the transaction, the insider owned 252,685 shares of the company’s stock, valued at approximately $1,369,552.70. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Mark Plavsic sold 12,169 shares of the firm’s stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $6.35, for a total transaction of $77,273.15. Following the completion of the transaction, the chief technology officer directly owned 197,287 shares of the company’s stock, valued at approximately $1,252,772.45. The trade was a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 39,223 shares of company stock valued at $233,155 in the last quarter. 6.30% of the stock is currently owned by corporate insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.